Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Profit After Tax: 2009-2024

Historic Profit After Tax for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to -$18.5 million.

  • Ani Pharmaceuticals' Profit After Tax rose 210.14% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 672.15%. This contributed to the annual value of -$18.5 million for FY2024, which is 198.63% down from last year.
  • As of FY2024, Ani Pharmaceuticals' Profit After Tax stood at -$18.5 million, which was down 198.63% from $18.8 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Profit After Tax high stood at $18.8 million for FY2023, and its period low was -$47.9 million during FY2022.
  • For the 3-year period, Ani Pharmaceuticals' Profit After Tax averaged around -$15.9 million, with its median value being -$18.5 million (2024).
  • In the last 5 years, Ani Pharmaceuticals' Profit After Tax slumped by 470.00% in 2020 and then surged by 139.21% in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Profit After Tax stood at -$22.5 million in 2020, then tumbled by 88.94% to -$42.6 million in 2021, then declined by 12.42% to -$47.9 million in 2022, then skyrocketed by 139.21% to $18.8 million in 2023, then crashed by 198.63% to -$18.5 million in 2024.